PharmaTher Holdings Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHRRF research report →
Price Chart
About the company
PharmaTher Holdings Ltd. is a biotechnology firm in the clinical stage, specializing in psychedelic treatments. Its primary objective is to investigate, develop, and bring to market innovative applications, drug forms, and administration techniques for psychedelics, addressing conditions such as mental health issues, neurological diseases, and chronic pain.
- CEO
- Fabio Chianelli
- IPO
- 2021
- Employees
- 5
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on PHRRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.91M
- P/E
- -4.55
- PEG
- -0.16
- P/S
- 0.00
- P/B
- 9.38
- EV/EBITDA
- -2.97
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -155.46%
- ROIC
- -241.01%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,523,637
- Net Income
- $-1,526,106+51.0%
- EPS
- $-0.02+51.3%
- OCF Growth
- +65.6%
- FCF Growth
- +65.6%
- 52W High
- $0.33
- 52W Low
- $0.03
- 50D MA
- $0.04
- 200D MA
- $0.06
- Beta
- 2.36
- RSI (14)
- 54
- Avg Volume
- 136.99K
No earnings-call transcripts are available for PHRRF yet.
- Free Float
- 80.8%
- Shares Outstanding
- 91.02M
- Float Shares
- 73.51M
Our PHRRF coverage
Recent articles, reports, and earnings notes.
No research on PHRRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHRRF report →PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
newsfilecorp.com · Aug 11
PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
newsfilecorp.com · Jul 29
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
newsfilecorp.com · Jul 27
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
newsfilecorp.com · Jul 21
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
feeds.newsfilecorp.com · Jul 15
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
newsfilecorp.com · May 27
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
newsfilecorp.com · May 13
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
newsfilecorp.com · May 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.